Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CYPHERPUNK TECHNOLOGIES INC.CYPH · Entity 6392 | Director | August 26, 2026 | August 27, 2026 |
| Eiger BioPharmaceuticals, Inc.EIGR · Entity 16554 | Director | March 01, 2023 | March 03, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CYPHERPUNK TECHNOLOGIES INC.
Report date August 26, 2026 · Filed August 27, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 132,500 |
Reported balance
After 2026-08-26 transaction · row 1
1 source rowRow 1 · 2026-08-26 · Sale · Disposed 20,000 · Balance 132,500 |
Eiger BioPharmaceuticals, Inc.
Report date March 01, 2023 · Filed March 03, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.71 · Expires 2033-02-28 | Direct | 40,000 |
Reported balance
After 2023-03-01 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-03-01 · Grant · Acquired 40,000 · Balance 40,000 F1: The option vests in equal monthly installments over 12 months measured from March 1, 2023, subject to Reporting Person's continuous service status as of each such date. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests in equal monthly installments over 12 months measured from March 1, 2023, subject to Reporting Person's continuous service status as of each such date.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Paratek Pharmaceuticals, Inc.
Report date September 21, 2023 · Filed September 21, 2023
Section 16 reporting ended · disclosed 2023-09-21. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 20,000 |
Reported balance
After 2023-09-21 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2023-09-21 · Disposition to issuer · Disposed 49,250 · Balance 20,000 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of June 6, 2023, by and among the Issuer, Resistance Acquisition, Inc. ("Parent"), and Resistance Merger Sub, Inc., a wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub merged with and into Issuer with the Issuer being the surviving corporation (the "Merger"). Pursuant to the Merger Agreement, as of the effective time of the Merger (the "Effective Time"), each issued and outstanding share of common stock of the Issuer ("Company Common Stock") was cancelled and retired and automatically converted into the right to receive (x) $2.15, payable to the holder thereof in cash, F2: (Continued from Footnote 1) without interest (the "Cash Consideration") but subject to reduction for any applicable withholding taxes payable in respect thereof and (y) one (1) contractual contingent value right (a "CVR Payment") that represents the right to receive $0.85 upon satisfaction of certain conditions set forth in a Contingent Value Rights Agreement, dated September 21, 2023, by and between Parent and Equiniti Trust Company, LLC. F3: Due to administrative error, the Reporting Person's previous Form 4 filings over-reported the securities beneficially owned by the Reporting Person by 750 shares of common stock of the Issuer. This filing corrects such error and lists the correct amount of securities beneficially owned directly by the Reporting Person. |
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2023-09-21 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2023-09-21 · Disposition to issuer · Disposed 20,000 · Balance 0 F4: Pursuant to the Merger Agreement, at the Effective Time, each restricted stock unit award covering shares of Company Common Stock that is subject to vesting conditions based solely on continued employment or service granted under an Issuer equity plan (each, a "Company RSU") and each performance stock unit award covering shares of Company Common Stock that are subject to performance-based vesting conditions granted under an Issuer equity plan (each, a "Company PSU") (the Company RSUs and the Company PSUs, collectively "Company Equity Awards") that was then outstanding was cancelled, and the holder of such cancelled Company Equity Award is entitled, in exchange therefor, to receive (without interest and less applicable tax withholdings) (i) an amount in cash equal to the product of (A) the total number of shares of Company Common Stock subject to (or deliverable under) such Company Equity Award immediately prior to the Effective Time multiplied by (B) the Cash Consideration, F5: (Continued from Footnote 4) and (ii) a CVR Payment for each share of Company Common Stock subject thereto (the "Equity Award Consideration"), provided, that any payment of the Equity Award Consideration in respect of an unvested Company Equity Award will remain subject to the same vesting conditions as were applicable to such Company Equity Award immediately prior to the Effective Time and shall only become payable to the holder of such cancelled Company Equity Award to the extent such vesting conditions are satisfied following the closing of the Merger. |
| Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.61 · Expires 2031-02-18 | Direct | 0 |
Reported balance
After 2023-09-21 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2023-09-21 · Disposition to issuer · Disposed 7,000 · Balance 0 F6: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Company Common Stock granted under an Issuer equity plan (each, a "Company Stock Option") that was then outstanding that has an exercise price per share of Company Common Stock that is greater than $3.00 was cancelled for no consideration. |
| Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.51 · Expires 2030-02-19 | Direct | 0 |
Reported balance
After 2023-09-21 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2023-09-21 · Disposition to issuer · Disposed 7,000 · Balance 0 F6: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Company Common Stock granted under an Issuer equity plan (each, a "Company Stock Option") that was then outstanding that has an exercise price per share of Company Common Stock that is greater than $3.00 was cancelled for no consideration. |
| Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.23 · Expires 2029-02-26 | Direct | 0 |
Reported balance
After 2023-09-21 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2023-09-21 · Disposition to issuer · Disposed 5,000 · Balance 0 F6: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Company Common Stock granted under an Issuer equity plan (each, a "Company Stock Option") that was then outstanding that has an exercise price per share of Company Common Stock that is greater than $3.00 was cancelled for no consideration. |
| Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $14.15 · Expires 2028-02-14 | Direct | 0 |
Reported balance
After 2023-09-21 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2023-09-21 · Disposition to issuer · Disposed 5,000 · Balance 0 F6: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Company Common Stock granted under an Issuer equity plan (each, a "Company Stock Option") that was then outstanding that has an exercise price per share of Company Common Stock that is greater than $3.00 was cancelled for no consideration. |
| Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $15.10 · Expires 2027-02-01 | Direct | 0 |
Reported balance
After 2023-09-21 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2023-09-21 · Disposition to issuer · Disposed 6,000 · Balance 0 F6: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Company Common Stock granted under an Issuer equity plan (each, a "Company Stock Option") that was then outstanding that has an exercise price per share of Company Common Stock that is greater than $3.00 was cancelled for no consideration. |
| Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $14.05 · Expires 2026-02-03 | Direct | 0 |
Reported balance
After 2023-09-21 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2023-09-21 · Disposition to issuer · Disposed 12,000 · Balance 0 F6: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Company Common Stock granted under an Issuer equity plan (each, a "Company Stock Option") that was then outstanding that has an exercise price per share of Company Common Stock that is greater than $3.00 was cancelled for no consideration. |
| Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $24.07 · Expires 2025-02-03 | Direct | 0 |
Reported balance
After 2023-09-21 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2023-09-21 · Disposition to issuer · Disposed 20,000 · Balance 0 F6: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Company Common Stock granted under an Issuer equity plan (each, a "Company Stock Option") that was then outstanding that has an exercise price per share of Company Common Stock that is greater than $3.00 was cancelled for no consideration. |
Filing footnotes · ownership attribution and instrument terms
F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of June 6, 2023, by and among the Issuer, Resistance Acquisition, Inc. ("Parent"), and Resistance Merger Sub, Inc., a wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub merged with and into Issuer with the Issuer being the surviving corporation (the "Merger"). Pursuant to the Merger Agreement, as of the effective time of the Merger (the "Effective Time"), each issued and outstanding share of common stock of the Issuer ("Company Common Stock") was cancelled and retired and automatically converted into the right to receive (x) $2.15, payable to the holder thereof in cash,
F2: (Continued from Footnote 1) without interest (the "Cash Consideration") but subject to reduction for any applicable withholding taxes payable in respect thereof and (y) one (1) contractual contingent value right (a "CVR Payment") that represents the right to receive $0.85 upon satisfaction of certain conditions set forth in a Contingent Value Rights Agreement, dated September 21, 2023, by and between Parent and Equiniti Trust Company, LLC.
F3: Due to administrative error, the Reporting Person's previous Form 4 filings over-reported the securities beneficially owned by the Reporting Person by 750 shares of common stock of the Issuer. This filing corrects such error and lists the correct amount of securities beneficially owned directly by the Reporting Person.
F4: Pursuant to the Merger Agreement, at the Effective Time, each restricted stock unit award covering shares of Company Common Stock that is subject to vesting conditions based solely on continued employment or service granted under an Issuer equity plan (each, a "Company RSU") and each performance stock unit award covering shares of Company Common Stock that are subject to performance-based vesting conditions granted under an Issuer equity plan (each, a "Company PSU") (the Company RSUs and the Company PSUs, collectively "Company Equity Awards") that was then outstanding was cancelled, and the holder of such cancelled Company Equity Award is entitled, in exchange therefor, to receive (without interest and less applicable tax withholdings) (i) an amount in cash equal to the product of (A) the total number of shares of Company Common Stock subject to (or deliverable under) such Company Equity Award immediately prior to the Effective Time multiplied by (B) the Cash Consideration,
F5: (Continued from Footnote 4) and (ii) a CVR Payment for each share of Company Common Stock subject thereto (the "Equity Award Consideration"), provided, that any payment of the Equity Award Consideration in respect of an unvested Company Equity Award will remain subject to the same vesting conditions as were applicable to such Company Equity Award immediately prior to the Effective Time and shall only become payable to the holder of such cancelled Company Equity Award to the extent such vesting conditions are satisfied following the closing of the Merger.
F6: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Company Common Stock granted under an Issuer equity plan (each, a "Company Stock Option") that was then outstanding that has an exercise price per share of Company Common Stock that is greater than $3.00 was cancelled for no consideration.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 21, 2019 Filed Mar 25, 2019 21:53 UTC | Eiger BioPharmaceuticals, Inc. EIGR · Entity 16554 | GrantStock Option ( Right to Buy) · Derivative | 20,000 | $0.00 Strike: $13.41 | $0.00 |
DisclosureSEC source: 0001209191-19-021281 · doc4.xml · derivative · entry 1 Dietz Thomas John · CIK 0001574218 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Shares · 20,000 shares Expires 2029-03-20 F1 · derivative.exercise_date: The option vests in equal monthly installments over 12 months measured from March 21, 2019 subject to Reporting Person's continuous service status as of each such date. Read SEC document |
| February 26, 2019 Filed Feb 28, 2019 18:26 UTC | Paratek Pharmaceuticals, Inc. PRTK · Entity 109529 | GrantStock Option (right to buy) · Derivative | 5,000 | $0.00 Strike: $7.23 | $0.00 |
DisclosureSEC source: 0000904454-19-000274 · edgar.xml · derivative · entry 2 Dietz Thomas John · CIK 0001574218 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 5,000 shares Expires 2029-02-26 F2 · derivative.exercise_price: The exercise price is equal to the closing sales price per share of the Issuer's common stock as reported on The Nasdaq Global Market on the date of grant. F3 · derivative.exercise_date: The stock option shall vest as to 1/12 of the shares subject to the stock option on the one-month anniversary following February 26, 2019, and on the same calendar date of each successive month thereafter until fully vested, subject to the Reporting Person's continued service with the Issuer through each vesting date. Read SEC document |
| February 26, 2019 Filed Feb 28, 2019 18:26 UTC | Paratek Pharmaceuticals, Inc. PRTK · Entity 109529 | GrantCommon Stock | 7,500 | $0.00 | $0.00 |
DisclosureSEC source: 0000904454-19-000274 · edgar.xml · nonDerivative · entry 1 Dietz Thomas John · CIK 0001574218 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,000 F1 · shares: Represents restricted stock units granted to the Reporting Person under the Paratek Pharmaceuticals, Inc. 2015 Equity Incentive Plan. Each restricted stock unit represents the contingent right to receive one share of the Issuer's common stock. The restricted stock units shall vest on the one-year anniversary of February 26, 2019, subject to the Reporting Person's continued service with the Issuer through the vesting date. 2. The exercise price is equal to the closing sales price per share of the Issuer's common stock as reported on The Nasdaq Global Market on the date of grant. Read SEC document |
| February 15, 2019 Filed Feb 20, 2019 16:57 UTC | Paratek Pharmaceuticals, Inc. PRTK · Entity 109529 | SaleCommon Stock | 3,000 | $7.14 | $21,420.00 |
DisclosureSEC source: 0000904454-19-000260 · edgar.xml · nonDerivative · entry 1 Dietz Thomas John · CIK 0001574218 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,500 F1 · shares: Sale of shares to cover personal income tax obligations upon vesting of restricted stock unit award, pursuant to Rule 10b5-1 trading plan. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions ranging from $7.09 to $7.20. The Reporting Person undertakes to provide to Paratek Pharmaceuticals, Inc., any security holder of Paratek Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote 2 to this Form 4. Read SEC document |
| January 01, 2019 Filed Jan 3, 2019 21:34 UTC | CYPHERPUNK TECHNOLOGIES INC. LPTX · Entity 6392 | GrantStock Option (Right to Buy) · Derivative | 9,375 | $0.00 Strike: $2.00 | $0.00 |
DisclosureSEC source: 0001104659-19-000508 · a4.xml · derivative · entry 1 Dietz Thomas John · CIK 0001574218 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,375 Underlying: Common Stock · 9,375 shares Expires 2028-12-31 F1 · derivative.exercise_date: The Option was granted pursuant to Leap's 2016 Equity Incentive Plan and shall vest and become exercisable in a series of 4 quarterly installments until the Option is fully vested, with the first such quarterly installment vesting on the three-month anniversary of January 1, 2019, the Vesting Start Date. Read SEC document |
| December 21, 2018 Filed Dec 26, 2018 16:05 UTC | Paratek Pharmaceuticals, Inc. PRTK · Entity 109529 | SaleCommon Stock | 9,330 | $5.01 | $46,743.30 |
DisclosureSEC source: 0000904454-18-000798 · edgar.xml · nonDerivative · entry 1 Dietz Thomas John · CIK 0001574218 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,500 F1 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions ranging from $5.00 to $5.03. The Reporting Person undertakes to provide to Paratek Pharmaceuticals, Inc., any security holder of Paratek Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote 1 to this Form 4. Read SEC document |
| December 20, 2018 Filed Dec 20, 2018 20:29 UTC | Eiger BioPharmaceuticals, Inc. EIGR · Entity 16554 | PurchaseCommon Stock | 5,000 | $9.98 | $49,900.00 |
DisclosureSEC source: 0001209191-18-063781 · doc4.xml · nonDerivative · entry 1 Dietz Thomas John · CIK 0001574218 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Read SEC document |
| December 06, 2018 Filed Dec 10, 2018 16:05 UTC | Eiger BioPharmaceuticals, Inc. EIGR · Entity 16554 | PurchaseCommon Stock | 5,000 | $11.26 | $56,300.00 |
DisclosureSEC source: 0001209191-18-061728 · doc4.xml · nonDerivative · entry 1 Dietz Thomas John · CIK 0001574218 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Read SEC document |
| April 18, 2018 Filed Apr 20, 2018 20:05 UTC | CYPHERPUNK TECHNOLOGIES INC. LPTX · Entity 6392 | GrantStock Option (Right to Buy) · Derivative | 11,250 | $0.00 Strike: $7.66 | $0.00 |
DisclosureSEC source: 0001104659-18-025613 · a4.xml · derivative · entry 1 Dietz Thomas John · CIK 0001574218 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,250 Underlying: Common Stock, $0.001 par value per share · 11,250 shares Expires 2028-04-17 F1 · derivative.exercise_date: The Option was granted pursuant to Leap's 2016 Equity Incentive Plan and shall vest and become exercisable in a series of 12 equal monthly installments until the Option is fully vested, with the first such monthly installment vesting on the one-month anniversary of April 18, 2018, the Vesting Start Date. F1 · derivative.underlying_shares: The Option was granted pursuant to Leap's 2016 Equity Incentive Plan and shall vest and become exercisable in a series of 12 equal monthly installments until the Option is fully vested, with the first such monthly installment vesting on the one-month anniversary of April 18, 2018, the Vesting Start Date. Read SEC document |
| March 14, 2018 Filed Mar 16, 2018 20:23 UTC | Eiger BioPharmaceuticals, Inc. EIGR · Entity 16554 | GrantStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $9.50 | $0.00 |
DisclosureSEC source: 0001209191-18-020453 · doc4.xml · derivative · entry 1 Dietz Thomas John · CIK 0001574218 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2028-03-13 F1 · derivative.exercise_date: The option vests in equal monthly installments over 12 months measured from March 14, 2018 subject to Reporting Person's continuous service status as of each such date. Read SEC document |
| February 14, 2018 Filed Feb 16, 2018 17:10 UTC | Paratek Pharmaceuticals, Inc. PRTK · Entity 109529 | GrantStock Option (right to buy) · Derivative | 5,000 | $0.00 Strike: $14.15 | $0.00 |
DisclosureSEC source: 0000904454-18-000195 · edgar.xml · derivative · entry 2 Dietz Thomas John · CIK 0001574218 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 5,000 shares Expires 2028-02-14 F2 · derivative.exercise_price: The exercise price is equal to the closing sales price per share of the Issuer's common stock as reported on The Nasdaq Global Market on the date of grant. F3 · derivative.exercise_date: The stock option was granted to the Reporting Person under the Paratek Pharmaceuticals, Inc. 2015 Equity Incentive Plan, pursuant to the Paratek Pharmaceuticals, Inc. Non-Employee Director Compensation Policy, effective January 1, 2018. The stock option shall vest as to 1/12 of the shares subject to the stock option on the one-month anniversary following February 14, 2018, and on the same calendar date of each successive month thereafter until fully vested, subject to the Reporting Person's continued service with the Issuer through each vesting date. Read SEC document |
| February 14, 2018 Filed Feb 16, 2018 17:10 UTC | Paratek Pharmaceuticals, Inc. PRTK · Entity 109529 | GrantCommon Stock | 7,500 | $0.00 | $0.00 |
DisclosureSEC source: 0000904454-18-000195 · edgar.xml · nonDerivative · entry 1 Dietz Thomas John · CIK 0001574218 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,830 F1 · shares: Represents restricted stock units granted to the Reporting Person under the Paratek Pharmaceuticals, Inc. 2015 Equity Incentive Plan, pursuant to the Paratek Pharmaceuticals, Inc. Non-Employee Director Compensation Policy, effective January 1, 2018. Each restricted stock unit represents the contingent right to receive one share of the Issuer's common stock. The restricted stock units shall vest on the one-year anniversary of February 14, 2018, subject to the Reporting Person's continued service with the Issuer through the vesting date. Read SEC document |
| February 05, 2018 Filed Feb 7, 2018 17:57 UTC | Paratek Pharmaceuticals, Inc. PRTK · Entity 109529 | SaleCommon Stock | 2,100 | $14.22 | $29,862.00 |
DisclosureSEC source: 0000904454-18-000127 · edgar.xml · nonDerivative · entry 1 Dietz Thomas John · CIK 0001574218 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,330 F1 · shares: Sale of shares to cover personal income tax obligations upon vesting of restricted stock unit award, pursuant to Rule 10b5-1 trading plan. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.00 to $14.43, inclusive. The Reporting Person undertakes to provide to Paratek Pharmaceuticals, Inc., any security holder of Paratek Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| April 12, 2017 Filed Apr 13, 2017 17:48 UTC | Eiger BioPharmaceuticals, Inc. EIGR · Entity 16554 | GrantStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $8.50 | $0.00 |
DisclosureSEC source: 0001209191-17-026902 · doc4.xml · derivative · entry 1 Dietz Thomas John · CIK 0001574218 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2027-04-12 F1 · derivative.exercise_date: The option vests in equal monthly installments over 12 months measured from April 12, 2017 subject to Reporting Person's continuous service status as of each such date. Read SEC document |
| February 02, 2017 Filed Feb 6, 2017 19:23 UTC | Paratek Pharmaceuticals, Inc. PRTK · Entity 109529 | GrantStock Option (right to buy) · Derivative | 6,000 | $0.00 Strike: $15.10 | $0.00 |
DisclosureSEC source: 0000904454-17-000107 · edgar.xml · derivative · entry 2 Dietz Thomas John · CIK 0001574218 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,000 Underlying: Common Stock · 6,000 shares Expires 2027-02-01 F2 · derivative.exercise_price: The exercise price is equal to the closing sales price per share of Common Stock as reported on The Nasdaq Global Market on the date of grant. F3 · derivative.exercise_date: The shares shall vest as to 1/12 of the shares on the one-month anniversary following February 2, 2017, and on the same calendar date of each successive month thereafter until fully vested, subject to the Reporting Person's continued service to the Company at each vesting date. Read SEC document |
| February 02, 2017 Filed Feb 6, 2017 19:23 UTC | Paratek Pharmaceuticals, Inc. PRTK · Entity 109529 | GrantCommon Stock | 6,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000904454-17-000107 · edgar.xml · nonDerivative · entry 1 Dietz Thomas John · CIK 0001574218 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,430 F1 · shares: The shares shall vest on the one-year anniversary of February 2, 2017, subject to the Reporting Person's continued service to the Company at the vesting date Read SEC document |
| January 23, 2017 Filed Jan 23, 2017 23:15 UTC | CYPHERPUNK TECHNOLOGIES INC. LPTX · Entity 6392 | GrantStock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $9.90 | $0.00 |
DisclosureSEC source: 0001104659-17-003614 · a4.xml · derivative · entry 2 Dietz Thomas John · CIK 0001574218 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock, $0.001 par value per share · 15,000 shares Expires 2027-01-22 F2 · derivative.exercise_date: The Option was granted pursuant to Leap's 2016 Equity Incentive Plan and shall vest and become exercisable in a series of 12 equal quarterly installments until the Option is fully vested, with the first such quarterly installment vesting on the three-month anniversary of January 23, 2017, the Vesting Start Date. F2 · derivative.underlying_shares: The Option was granted pursuant to Leap's 2016 Equity Incentive Plan and shall vest and become exercisable in a series of 12 equal quarterly installments until the Option is fully vested, with the first such quarterly installment vesting on the three-month anniversary of January 23, 2017, the Vesting Start Date. Read SEC document |
| January 23, 2017 Filed Jan 23, 2017 23:15 UTC | CYPHERPUNK TECHNOLOGIES INC. LPTX · Entity 6392 | GrantStock Option (Right to Buy) · Derivative | 11,000 | $0.00 Strike: $9.90 | $0.00 |
DisclosureSEC source: 0001104659-17-003614 · a4.xml · derivative · entry 1 Dietz Thomas John · CIK 0001574218 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,000 Underlying: Common Stock, $0.001 par value per share · 11,000 shares Expires 2027-01-22 F1 · derivative.exercise_date: The Option was granted pursuant to Leap's Amended and Restated 2012 Equity Incentive Plan and is fully vested as of the grant date. F1 · derivative.underlying_shares: The Option was granted pursuant to Leap's Amended and Restated 2012 Equity Incentive Plan and is fully vested as of the grant date. Read SEC document |
| March 28, 2016 Filed Sep 15, 2016 14:41 UTC Amendment | Eiger BioPharmaceuticals, Inc. EIGR · Entity 16554 | GrantStock Option (Right to Buy) · Derivative | 23,000 | $0.00 Strike: $15.75 | $0.00 |
DisclosureSEC source: 0001209191-16-141542 · doc4a.xml · derivative · entry 2 Dietz Thomas John · CIK 0001574218 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,000 Underlying: Common Stock · 23,000 shares Expires 2026-03-28 F2 · derivative.exercise_date: The option grant was approved by Issuer's board of directors on March 28, 2016, subject to stockholder approval of an amendment of the Issuer's 2013 Equity Incentive Plan (the "Plan") under which the option was granted. Issuer's stockholders approved the amendment to the Plan on August 29, 2016. F3 · derivative.exercise_date: The option vests in equal monthly installments over 24 months measured from March 28, 2016 subject to Reporting Person's continuous service status as of each such date. Read SEC document |
| March 28, 2016 Filed Sep 15, 2016 14:41 UTC Amendment | Eiger BioPharmaceuticals, Inc. EIGR · Entity 16554 | GrantStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $15.75 | $0.00 |
DisclosureSEC source: 0001209191-16-141542 · doc4a.xml · derivative · entry 1 Dietz Thomas John · CIK 0001574218 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2026-03-28 F1 · derivative.exercise_date: The option vests in equal monthly installments over 12 months measured from March 28, 2016 subject to Reporting Person's continuous service status as of each such date. F2 · derivative.exercise_date: The option grant was approved by Issuer's board of directors on March 28, 2016, subject to stockholder approval of an amendment of the Issuer's 2013 Equity Incentive Plan (the "Plan") under which the option was granted. Issuer's stockholders approved the amendment to the Plan on August 29, 2016. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.